Pharmaceutical Benefits Advisory Committee (PBAC) Submission

The Pharmaceutical Benefits Advisory Committee (PBAC) will assess a new treatment for generalised MG patients in early 2024 and we have the opportunity to make a consumer submission. This means we can share our lived experience with national decision makers and help to ensure new treatment options are available, accessible, and affordable.
Your response to the following questions will help inform the submission to be put forward by the MAA on behalf of our patient community.
1.Do you feel your Myasthenia Gravis condition and symptoms are well-controlled by current treatments? 
2.Is your current treatment regime keeping you stable and allowing you to undertake daily activities including meeting work and/or other commitments? 
3.Do you feel that your MG, including side effects from treatments, is a burden when managing your life/lifestyle physically, emotionally, and/or financially? 
4.Do you have regular fluctuations with your MG and does this create uncertainty for you?
5.Have you had an MG crisis or flare in the last 12 months?